A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
Status:
Completed
Trial end date:
2002-01-01
Target enrollment:
Participant gender:
Summary
This is a randomized study of combination chemotherapy (EPOCH II) versus EPOCH II and
immunotherapy with peripheral blood stem cells (PBSC) and IL-2 in patients with relapsed
Hodgkin's and non-Hodgkin's lymphomas, and untreated patients with low-grade non-Hodgkin's
lymphomas. The chemotherapy entails the administration of multiple cycles of infusional
doxorubicin, etoposide and vincristine chemotherapy (total of 3), alternating with cycles of
high-dose cyclophosphamide (3 cycles). Patients will be randomized, on a 2:1 basis, to either
receive only chemotherapy or to undergo a PBSC harvest with PBSC reinfusion and IL-2
following the last cycle of chemotherapy. In all patients, immunological monitoring for
NK/LAK activity, T cell number and function will be performed. The therapy is specifically
targeted for patients who would be candidates for high-dose chemotherapy with stem cell
support.